Senator Ben Sasse Shares Hope After Cancer Diagnosis
Former U.S. Senator Ben Sasse recently opened up about his fight against stage 4 pancreatic cancer and the experimental treatment that is giving him new hope. Sasse, who served Nebraska from 2015 to 2023, announced his diagnosis in December 2025. His cancer has spread to other organs, including his liver and lungs.
When he was initially told he only had a few months to live, Sasse joined a clinical trial for a drug called daraxonrasib. This oral medication targets specific genes that contribute to cancer growth. Within just four months of starting the treatment, Sasse reported a significant reduction in his pain and a 76% decrease in tumor size.
Daraxonrasib works by disrupting a crucial growth “switch” found in many cancers, according to Dr. Sarbajit Mukherjee, an oncologist at the Miami Cancer Institute. “In pancreatic cancer, this switch is usually stuck in the ‘on’ position, leading to uncontrolled growth,” he explained. The drug helps to “turn down” this signal, potentially slowing or even shrinking the cancer.
In a recent interview, Sasse reflected on his treatment journey, stating, “I feel much better now than I did four months ago.” He highlighted that the clinical trial results are promising, showing a median survival rate of 13 months for participants, compared to about six months for those continuing standard chemotherapy.
Experts say this targeted therapy is a significant advance in treating a disease that is notoriously hard to diagnose early. Dr. Marc Siegel noted that this approach could fundamentally change how treatments are developed for pancreatic cancer, which has historically made slow progress.
Although the treatment is not yet FDA-approved, early findings are encouraging. Mukherjee mentioned that combining daraxonrasib with traditional chemotherapy has led to even better results in shrinking tumors.
Sasse credits both the drug and his faith as vital to his journey. “It’s strange to receive a terminal diagnosis in your early 50s,” he said. Despite the challenges, he feels there is still much to learn and discuss around this experience.
Looking ahead, ongoing trials aim to determine how daraxonrasib could be integrated into first-line treatments for pancreatic cancer. While the medication has some side effects, it is generally better tolerated than many conventional therapies.
As he continues his battle, Sasse remains optimistic and encouraged by the support and advancements in treatment. “I don’t have all the answers,” he said, “but there is much we can reflect on together.”
